Pharmacoeconomics of HIV-infection
Autor: | R. I. Yagudina, A. U. Kulikov, V. V. Babiy, E. E. Arinina |
---|---|
Jazyk: | ruština |
Rok vydání: | 2018 |
Předmět: |
фармакоэкономический анализ
Medicine (General) human immunodeficiency virus (hiv) приверженность virus diseases modeling анализ затрат моделирование pharmacoeconomic analysis epidemics эпидемия анализ «влияния на бюджет» вирус иммунодефицита человека (вич) критерии эффективности R5-920 effectiveness analysis антиретровирусная терапия (арт) cost analysis effectiveness criteria burden of the disease бремя заболевания budget impact analysis анализ эффективности adherence antiretroviral therapy (art) |
Zdroj: | Ведомости Научного центра экспертизы средств медицинского применения, Vol 0, Iss 4, Pp 58-63 (2018) |
ISSN: | 2619-1172 1991-2919 |
Popis: | Ever since the first registrations of HIV-infections at the territory of the Russian Federation there was started a great process on arrangement and, subsequently, development of anti-HIV system. It should be noted, that increase of HIV screening and number of patients on antiretroviral treatment are the most important features of the system. Nevertheless, experts note the continuing growth of the size of infected population and, that is more important, the escape of HIV-epidemics from the groups with risk behaviors to the general population, therefore it is necessary to further increase the effectiveness of activities against HIV-spreading. In particular, it is necessary to use more rational (in the context of both the effectiveness, safety and cost) in present settings medical technologies. Pharmacoeconomic analysis is an appropriate instrument for these challenges. However pharmacoeconomic analysis within HIV-infection, like within all other disease areas, has some planning and conducting specialties. We formulated some key aspects of pharmacoeconomic analysis within HIV-infection: need for modelling; use of several criteria (virological, immunological, clinical and epidemiological); consideration of adherence to the therapy; consideration of complications costs; consideration of indirect costs. |
Databáze: | OpenAIRE |
Externí odkaz: |